Lauer Wealth LLC Trims Stake in Tempus AI, Inc. $TEM

Lauer Wealth LLC cut its stake in shares of Tempus AI, Inc. (NASDAQ:TEM) by 54.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,200 shares of the company’s stock after selling 13,400 shares during the period. Tempus AI comprises about 0.6% of Lauer Wealth LLC’s investment portfolio, making the stock its 21st biggest position. Lauer Wealth LLC’s holdings in Tempus AI were worth $904,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC bought a new position in shares of Tempus AI in the second quarter worth about $54,020,000. Geode Capital Management LLC increased its holdings in Tempus AI by 411.4% in the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock worth $41,264,000 after acquiring an additional 522,443 shares in the last quarter. KADENSA CAPITAL Ltd purchased a new stake in Tempus AI in the 1st quarter worth approximately $22,130,000. Marex Group plc bought a new stake in Tempus AI during the 2nd quarter worth approximately $26,620,000. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in Tempus AI by 1,747.6% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock valued at $26,247,000 after purchasing an additional 390,723 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TEM. Morgan Stanley increased their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Canaccord Genuity Group cut their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. JPMorgan Chase & Co. decreased their price target on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Finally, Guggenheim lifted their target price on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, September 26th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $84.00.

Tempus AI Trading Down 1.8%

Shares of Tempus AI stock opened at $60.39 on Wednesday. Tempus AI, Inc. has a twelve month low of $31.36 and a twelve month high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The business has a 50-day moving average price of $73.96 and a 200-day moving average price of $73.62. The firm has a market cap of $10.74 billion, a price-to-earnings ratio of -50.75 and a beta of 4.99.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The company’s revenue for the quarter was up 84.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.46) EPS. Equities research analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Insider Transactions at Tempus AI

In other news, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the sale, the chief financial officer directly owned 111,250 shares in the company, valued at approximately $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Erik Phelps sold 1,302 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $67.42, for a total transaction of $87,780.84. Following the sale, the executive vice president directly owned 89,280 shares of the company’s stock, valued at $6,019,257.60. This represents a 1.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 932,832 shares of company stock valued at $71,324,324. Company insiders own 26.27% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.